Lyell Immunopharma (LYEL) Net Cash Flow (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Net Cash Flow data on file, last reported at $30.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 107.69% year-over-year to $30.6 million; the trailing twelve-month figure through Mar 2026 stood at -$29.7 million (down 656.63% YoY), and the FY2025 full-year result was -$45.5 million, down 17.8% from the prior year.
• Net Cash Flow advanced to $30.6 million in Q1 2026, from -$63.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $114.9 million in Q2 2023 to a low of -$140.6 million in Q4 2023.
• A 5-year average of -$11.9 million and a median of -$14.1 million in 2023 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 781.89% in 2023, while the deepest fall reached 2040.45% in 2023.
• Tracing LYEL's Net Cash Flow over 5 years: stood at $7.2 million in 2022, then sank by 2040.45% to -$140.6 million in 2023, then jumped by 104.77% to $6.7 million in 2024, then sank by 1046.18% to -$63.4 million in 2025, then soared by 148.25% to $30.6 million in 2026.
• Business Quant data shows LYEL's Net Cash Flow at $30.6 million in Q1 2026, -$63.4 million in Q4 2025, and $24.8 million in Q3 2025.